HR positive

WATCH: @YAbdouMD, of @UNC_Lineberger, discusses updates in the treatment of patients with HR-positive, HER2-negative breast cancer. #bcsm #oncology https://t.co/bm3XbNunzN (@OncLive)

Continued research efforts have solidified the use of targeted therapies in HR-positive breast cancer and indicate the importance of further research with HER3-directed ADCs in metastatic disease. @maryam_lustberg @SmilowCancer @ASCO #ASCO23 #bcsm https://t.co/dJIGDZReL7 (@OncLive)

Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in HR-positive breast cancer, the future of ADCs in TNBC, and the importance of a shared decision-making process in breast cancer treatment. @drsarahsam @DanaFarber #bcsm #oncology https://t.co/eAR3QZt7Pa (@OncLive)

🏆 Huge congrats to my friend @Lucarecco from @UniGenova @SanMartino_Ge on an outstanding presentation at #ESHRE2023! Proud to be a co-author of this important work, confirming the safety of #pregnancy after hormone receptor-positive #BreastCancer diagnosis. @OncoAlert 🥇🚀 (@boutrosand)

Breast Cancer Research: Final results of TROPiCS-02 reported at #ASCO23. Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer Read more ➡️ https://t.co/mBMz5ZnZox CC: @DFCI_BreastOnc @STolaney1 (@DanaFarberNews)

Prof Carlo Palmieri @cancermedic from @CCCNHS who with Prof Charles Coombes @imperialcollege co-authored our #ASCO23 poster outlining validation of @digistain novel approach to predicting outcomes in adjuvant therapy decision making for hormone receptor-positive #breastcancer (@digistain)

Impact of #HER2LOW expression in the #Oncotype DX RS in patients with operable hormone receptor positive early-stage #breastcancer @LauraSofiaMuno9 @MCristofanill @ASCO #ASCO23 (@CtcLaboratory)

Circulating tumor cells (#CTCs) dynamics after CDK4/6i for hormone receptor positive (HR+) #metastaticbreastcancer (MBC): a biomarker analysis of the PACE randomized phase II study @LGerratana @MCristofanill @CroAviano @WCM_MeyerCancer @DFCI_BreastOnc (@CtcLaboratory)

Presented at #ASCO23 very important data from the #SOFT trial to increase our understanding of the biology of hormone receptor-positive/HER2-negative #BreastCancer in premenopausal women: congratulations @LoiSher @etop_ibcsg et all! @OncoAlert (@matteolambe)

The addition of ribociclib to endocrine therapy extended invasive DFS for patients with hormone receptor-positive, HER2-negative early-stage breast cancer #ASCO23 @UCLAJCCC @MDAndersonNews @NovartisCancer @DrDebuTripathy #Kisqali #NATALEE https://t.co/je2JJdsf0t (@HemOncToday)

Lerociclib/Fulvestrant May Reduce Risk of Disease Progression in Advanced HR-Positive/HER2-Negative Breast Cancer https://t.co/TWzsHInxAr @ASCO #ASCO23 @glopesMD (@GlopesMd)

@ASCO Abstract # 575 'Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.' #ASCO23 @LauraSofiaMuno9 @eleonora_nicolo @eleniandreop @JeannineDonahue @MCristofanill @LANewmanMD @CiglerTessa (@CtcLaboratory)

In metastatic breast cancer treated with targeted therapy and endocrine therapy, new research shows no difference in survival between patients with HR positive disease with low HER2 vs. those with no HER2 expression https://t.co/lqEwgZXAf3 @ASCOPost @JAMouabbi #EndCancer (@MDAndersonNews)

The TOT-HER3 study investigated HER3-DXd in previously untreated HR+positive/HER2- tumors early breast cancer in cohorts with different ERBB3 mRNA expression levels. Change in CelTIL score was the primary endpoint https://t.co/6Py1TBx9sv @_SOLTI @MOliveira_MD @prat_aleix #bcsm (@Annals_Oncology)

Adjuvant treatment decisions among adults aged 65 years and older with early-stage hormone receptor positive breast cancer seen in a simple multidisciplinary clinic versus standard consultation https://t.co/wl0SGRRYmP @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults (@JGeriOnc)

Check out the Society's Newly Revised Resource Guide to Endocrine Management of Hormone Receptor Positive Breast Cancer. @SBoolbol @AnjaliThawaniMD @DrJudyBoughey https://t.co/wEKWUEkrMH (@ASBrS)

1/4 Happy to share our newly published @MDAndersonNews paper where we investigated whether #HER2low status is a prognostic factor in #metastatic hormone receptor positive #breastcancer #bcsm https://t.co/plvHqwYo3t (@JAMouabbi)

Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor-Positive Breast… https://t.co/ldv8nKQjkM Very nice paper! Congrats to French colleagues for shedding lights on recurrence vs second primary BC! (@FilippoMontemu1)

Watch Dr. Jennifer Litton discuss treatment recommendations and supporting research on use of endocrine therapy and CDK4/6 inhibitors for both metastatic and high-risk, early HR positive/HER2 negative breast cancer. https://t.co/b2WPpFRNbp @MDEdgeTweets @JenniferLitton #EndCancer (@MDAndersonNews)

New📰in Current Treatment Options in Oncology from Dr. Erica Mayers and Dr. Jamie Brett discussing new developments in systemic management for high-risk early-stage hormone-receptor-positive, HER2-negative breast cancer. @elmayermd #breastcancer 👉https://t.co/kJMnlxuaxX (@DFCI_BreastOnc)

Meet Central California Hematology Oncology Conference faculty, Dr. @gandhi_shipra of @RoswellPark! Dr. Gandhi will present "Updates in Hormone Receptor-Positive and HER-2 Negative Breast Cancers." REGISTER: https://t.co/6bqVmdACkm #BTFCentralCA #JuneEvents #2023Events #CME (@btfoundation)

also, stay tuned for this mini-oral from my group! 3MO - HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial (ID 48) @_SOLTI… https://t.co/rfUtZabNh8 (@prat_aleix)

Breast cancer treatment de-escalation:Multigene assays have been used to avoid chemotherapy in patients with hormone receptor-positive tumours, human epidermal growth factor receptor 2-negative tumours, and a low recurrence score, in addition to individuals with nodal involvement (@singhv2003)

A6: Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06) NCT04494425 #HER2low #PathTwitter #BreastPath https://t.co/SOhzkLVX4Q (@KhouryThaer)

As indications for novel ADCs expand in TNBC & HR-positive, HER2-negative breast cancer, researchers continue attempts to move these agents into earlier treatment lines. @DrSGraff @WilliamSikov @Rhodeislandmd @LifespanHlthSys @OncLiveSOSS #bcsm #OncLiveIPC https://t.co/0BtaYSEMRD (@OncLive)

In this #OpenAccess review, @laura_huppert et al discuss current and emerging therapies for both early-stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data 🔗 https://t.co/TS4avPLsog @Idossa_MD @hoperugo (@CAonline)

A recent study of premenopausal women with HR positive, HER2 positive breast cancer may lead to a more personalized approach to therapy for these patients. Our Dr. Jasmine Sukumar explains: https://t.co/5h966RrSzT @JasmineSukumar #BreastCancer #Research #EndCancer (@MDAndersonNews)

The EAY191-N2/ComboMATCH patient study webpage is now LIVE! Learn more about this treatment trial for people who have hormone receptor-positive metastatic #breastcancer with NF1 mutation. https://t.co/GUp26hJaCs @naborala (@NRGonc)

Our @bcmhouston @BCMCancerCenter #bcsm SPORE project 1 - #comboMATCH @NRGonc trial targeting nonsense, frameshift mutation of NF1 for hormone receptor-positive metastatic breast cancer trial is open for screening!!!! (@naborala)

Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective BioItaLEE trial https://t.co/1qdrIoP8b8 So proud to be part of this! TKI is a very promising, low cost biomarker! (@FilippoMontemu1)

Learn about new research led by our Dr. Jasmine Sukumar about adjuvant endocrine therapy and ovarian suppression in premenopausal women with HR positive, HER2 positive breast cancer. https://t.co/6n3qdSoRM9 @JasmineSukumar #BreastCancer #Research #EndCancer (@MDAndersonNews)

''Optimizing treatment for HER2-positive HR-positive breast cancer'' 🔹Triple-positive breast cancer has a unique biology 🔹ER and HER2 pathways are closely related 🔹ER expression influences response to anti-HER2 therapies A great review👇 https://t.co/xSYuL19KKN (@dr_yakupergun)

There are more patients with germ-line BRCA mutation in hormone receptor positive metastatic breast cancer than TNBC per Dr @DrWGradishar. #bcsm (@teamoncology)

I believe HER2 expression is important in TNBC, although not in HR-positive BC. There is a significant, albeit marginal, trend in favor of HER-low in stages 2, 3 and 4. I believe this difference will become clear when we separate HER2 0+ and 1+ more accurately. (@dr_yakupergun)

🍀Share a review article: Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours By Dr. Masakazu Toi 👉https://t.co/AtPKWE00r6 #HER2 #Resistance #microbiome #breastcancer @DrHBurstein @CShahMD @Dr_RShatsky (@cdrjournal)

FDA Approves Sacituzumab Govitecan-hziy for Pretreated Patients With HR-Positive, HER2-Negative Breast Cancer - The ASCO Post Great news!! Two #MBC approvals in a week! 👏👏 #bcsm https://t.co/S1oxtktndN (@drteplinsky)

Just Out (via @ASCO Post) @US_FDA @FDAOncology 🇺🇸Approves sacituzumab govitecan in unresectable, locally advanced or mets HR positive, HER2-negative🧬 #BreastCancer who received ET💊 & at least 2⃣additional systemic tx @OncoAlert 🚨 based on TROPiCS-02 https://t.co/ZRxQP1rdWc (@weoncologists)

Great news! Another Rx option for HR positive MBC that improves OS. @oncoalert. Now sequencing is the big Q. U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer https://t.co/h9JlVees6w (@hoperugo)

Just received @ASCO @AACR @FDAOncology 🚨 We officially Oserdu (see what they did there? O-SERD-u?)—elacestrant for mutESR1 hormone receptor positive breast cancer w/new companion diagnostic @Guardant360CDx for mutESR1 detection. Label: https://t.co/KYQYSX1JFI @OncoAlert #bcsm ()

On NOW at #OncoAlertColloquium 🚨 @E_de_Azambuja on Early HR positive HER2 positive Breast Cancer‼️ https://t.co/JEiyFhKWOz (@OncoAlert)

A single-institutional retrospective review of real-world data showed the use of ovarian suppression was uncommon in premenopausal patients with HR-positive, HER2-positive breast cancer. @maryam_lustberg @YaleCancer #bcsm https://t.co/ujn8AyWxVH (@OncLive)

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial https://t.co/EbRGcGlZVr (@MLPOncoData)